JP2004527505A - Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法 - Google Patents

Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法 Download PDF

Info

Publication number
JP2004527505A
JP2004527505A JP2002571029A JP2002571029A JP2004527505A JP 2004527505 A JP2004527505 A JP 2004527505A JP 2002571029 A JP2002571029 A JP 2002571029A JP 2002571029 A JP2002571029 A JP 2002571029A JP 2004527505 A JP2004527505 A JP 2004527505A
Authority
JP
Japan
Prior art keywords
microparticles
weight
acid
polymer
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002571029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527505A5 (enExample
Inventor
ブリータ・シェーブロム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004527505A publication Critical patent/JP2004527505A/ja
Publication of JP2004527505A5 publication Critical patent/JP2004527505A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002571029A 2001-03-09 2002-03-06 Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法 Pending JP2004527505A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100823A SE0100823D0 (sv) 2001-03-09 2001-03-09 Method I to obtain microparticles
PCT/SE2002/000399 WO2002072070A1 (en) 2001-03-09 2002-03-06 Method to obtain microparticles containing a h+, k+-atp-ase inhibitor

Publications (2)

Publication Number Publication Date
JP2004527505A true JP2004527505A (ja) 2004-09-09
JP2004527505A5 JP2004527505A5 (enExample) 2005-12-22

Family

ID=20283294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002571029A Pending JP2004527505A (ja) 2001-03-09 2002-03-06 Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法

Country Status (9)

Country Link
US (1) US20040131689A1 (enExample)
EP (1) EP1370242A1 (enExample)
JP (1) JP2004527505A (enExample)
CN (1) CN1507344A (enExample)
AU (1) AU2002235100B8 (enExample)
CA (1) CA2440158A1 (enExample)
NZ (1) NZ527996A (enExample)
SE (1) SE0100823D0 (enExample)
WO (1) WO2002072070A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023151957A (ja) * 2022-04-01 2023-10-16 理研ビタミン株式会社 薬物含有粒子の製造方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060159756A1 (en) * 1999-09-10 2006-07-20 Brita Sjoblom Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6607784B2 (en) 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
FR2845915B1 (fr) 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
DE102005001162A1 (de) * 2005-01-10 2006-07-20 Haemosys Gmbh Adsorptionssystem zur Entfernung von Viren und viralen Bestandteilen aus Flüssigkeiten, insbesondere aus Blut und Blutplasma
JP2009514884A (ja) * 2005-11-04 2009-04-09 イーストマン ケミカル カンパニー 難溶性医薬活性剤の投与のためのカルボキシアルキルセルロースエステル
US20090068263A1 (en) * 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
GB0707612D0 (en) 2007-04-19 2007-05-30 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
EP2044929A1 (en) * 2007-10-04 2009-04-08 Laboratorios del Dr. Esteve S.A. Oral fast distintegrating tablets
CN102512382B (zh) * 2011-12-23 2013-09-04 天津市汉康医药生物技术有限公司 供注射用埃索美拉唑钠药物组合物
DE102019133243A1 (de) * 2019-12-05 2021-06-10 Rheinische Friedrich-Wilhelms-Universität Bonn Verfahren zur Herstellung sprühgefriergetrockneter Partikel und entsprechend hergestellte Partikel

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3721725A (en) * 1970-08-14 1973-03-20 Du Pont Process for preparing powder blends
US3932943A (en) * 1970-08-14 1976-01-20 E. I. Du Pont De Nemours And Company Method of preparation of lyophilized biological products
US4526734A (en) * 1981-03-05 1985-07-02 Ibigawa Electric Industry Co., Ltd. Process for the production of silicon carbide sintered bodies
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5017383A (en) * 1989-08-22 1991-05-21 Taisho Pharmaceutical Co., Ltd. Method of producing fine coated pharmaceutical preparation
US5102983A (en) * 1990-04-02 1992-04-07 United States Surgical Corporation Process for preparing foamed, bioabsorbable polymer particles
DE4201179A1 (de) * 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
GB2329124B (en) * 1997-09-12 2002-05-08 Hiran Asoka Malinga Ratwatte Method of forming dose units of active agents
JP4980527B2 (ja) * 1999-06-07 2012-07-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性化合物を含有する新規の製剤および投与形
SE9903236D0 (sv) * 1999-09-10 1999-09-10 Astra Ab Method to obtain microparticles
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100824D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method III to obtain microparticles

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023151957A (ja) * 2022-04-01 2023-10-16 理研ビタミン株式会社 薬物含有粒子の製造方法

Also Published As

Publication number Publication date
EP1370242A1 (en) 2003-12-17
WO2002072070A1 (en) 2002-09-19
AU2002235100B8 (en) 2006-08-31
SE0100823D0 (sv) 2001-03-09
CA2440158A1 (en) 2002-09-19
AU2002235100B2 (en) 2006-07-13
CN1507344A (zh) 2004-06-23
US20040131689A1 (en) 2004-07-08
NZ527996A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
JP2004527505A (ja) Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法
AU2002235100A1 (en) Method to obtain microparticles containing A H+, K+ -ATP-ase inhibitor
US6753014B1 (en) Method to obtain microparticles
US7785630B2 (en) Preparation and administration form comprising an acid-labile active compound
CA2214027C (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
JP2004522796A (ja) Ｈ＋，ｋ＋−ａｔｐアーゼ阻害剤を含む微粒子の製造方法
KR101141508B1 (ko) 판토프라졸 복합 미립자 제형
PL192437B1 (pl) Kompozycja farmaceutyczna do podawania doustnego zawierająca 2-[[(2-pirydynylo)metylo]sulfinylo]benzimidazol i sposób otrzymywania tej kompozycji
AU2002235101A1 (en) Method to obtain microparticles containing A H+, K+ -ATP-ase inhibitor
JP2001163769A (ja) シロスタゾール製剤
US20060159756A1 (en) Method to obtain microparticles containing an H+,K+-ATP-ASE inhibitor
WO2005023225A1 (en) Cilostazol adsorbate
HK1059896B (en) Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090414